{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T13:15:05Z","timestamp":1775654105064,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24KK0207"],"award-info":[{"award-number":["JP24KK0207"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Poly (ADP-ribose) polymerase (PARP) inhibitors provide clinical benefit for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    pathogenic variants. This study aimed to investigate the genomic landscape of mCRPC and evaluate the prognostic and therapeutic impact of pathogenic\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    variants. We conducted a retrospective cohort study of 5893 patients with mCRPC registered in Japan. Overall survival (OS) was compared according to homologous recombination repair (HRR) gene alteration status and specific\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    pathogenic variants. Of 5893 patients, 2203 carried at least one pathogenic variant in HRR genes, and 792 had\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    pathogenic variants. Olaparib was recommended for all patients with\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    pathogenic variants, of whom 389 received the treatment. Patients with HRR gene alterations had significantly shorter OS than those without (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.023). Among olaparib-treated patients,\n                    <jats:italic>BRCA1<\/jats:italic>\n                    pathogenic variants were significantly associated with worse OS compared with\n                    <jats:italic>BRCA2<\/jats:italic>\n                    pathogenic variants (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.008). Within\n                    <jats:italic>BRCA2<\/jats:italic>\n                    -altered cases,\n                    <jats:italic>BRCA2<\/jats:italic>\n                    loss was associated with the most favorable OS (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). Multivariate analysis confirmed\n                    <jats:italic>BRCA1<\/jats:italic>\n                    pathogenic variants as an independent adverse prognostic factor and\n                    <jats:italic>BRCA2<\/jats:italic>\n                    loss as an independent favorable factor in patients treated with olaparib. These findings highlight the clinical importance of detailed genomic annotation for precision oncology in mCRPC.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01339-8","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:23:22Z","timestamp":1772115802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic landscape and clinical impact of BRCA1\/2 pathogenic variants in metastatic castration-resistant prostate cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Kazuki","family":"Iida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusei","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juntaro","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"1339_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L. et al. Cancer statistics, CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"1339_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424\u2013433 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1339_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan, C. J. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16, 152\u2013160 (2015).","journal-title":"Lancet Oncol."},{"key":"1339_CR4","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi, K. N. et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J. Clin. Oncol. 39, 2294\u20132303 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1339_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med 351, 1502\u20131512 (2004).","journal-title":"N. Engl. J. Med"},{"key":"1339_CR6","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015).","journal-title":"Cell"},{"key":"1339_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard, C. C. et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N. Engl. J. Med. 375, 443\u2013453 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1339_CR8","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","volume":"22","author":"AM Aparicio","year":"2016","unstructured":"Aparicio, A. M. et al. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin. Cancer Res. 22, 1520\u20131530 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1339_CR9","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1172\/JCI132031","volume":"130","author":"J Mateo","year":"2020","unstructured":"Mateo, J. et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J. Clin. Invest. 130, 1743\u20131751 (2020).","journal-title":"J. Clin. Invest."},{"key":"1339_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.23.00339","volume":"42","author":"J Mateo","year":"2024","unstructured":"Mateo, J. et al. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and\/or BRCA2 in the PROfound Trial. J. Clin. Oncol. 42, 571\u2013583 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1339_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10147-020-01831-6","volume":"26","author":"Y Naito","year":"2021","unstructured":"Naito, Y. et al. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J. Clin. Oncol. 26, 233\u2013283 (2021).","journal-title":"Int J. Clin. Oncol."},{"key":"1339_CR12","doi-asserted-by":"crossref","unstructured":"Ebi, H. et al. Precision Oncology and the Universal Health Coverage System in Japan. JCO Precis. Oncol. 3, PO.19.00291 (2019).","DOI":"10.1200\/PO.19.00291"},{"key":"1339_CR13","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","volume":"12","author":"T Kohno","year":"2022","unstructured":"Kohno, T. et al. C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan. Cancer Discov. 12, 2509\u20132515 (2022).","journal-title":"Cancer Discov."},{"key":"1339_CR14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","volume":"35","author":"D Olmos","year":"2024","unstructured":"Olmos, D. et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann. Oncol. 35, 458\u2013472 (2024).","journal-title":"Ann. Oncol."},{"key":"1339_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/jnci\/djz124","volume":"112","author":"Y Momozawa","year":"2020","unstructured":"Momozawa, Y. et al. Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls. J. Natl. Cancer Inst. 112, 369\u2013376 (2020).","journal-title":"J. Natl. Cancer Inst."},{"key":"1339_CR16","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.cgh.2020.12.007","volume":"20","author":"M Fujita","year":"2022","unstructured":"Fujita, M. et al. Population-based Screening for Hereditary Colorectal Cancer Variants in Japan. Clin. Gastroenterol. Hepatol. 20, 2132\u20132141.e9 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1339_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/JU.0000000000001570","volume":"205","author":"N Shore","year":"2021","unstructured":"Shore, N. et al. Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations. J. Urol. 205, 977\u2013986 (2021).","journal-title":"J. Urol."},{"key":"1339_CR18","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1002\/cam4.5333","volume":"12","author":"H Uemura","year":"2023","unstructured":"Uemura, H. et al. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study. Cancer Med. 12, 5265\u20135274 (2023).","journal-title":"Cancer Med."},{"key":"1339_CR19","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro, E. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J. Clin. Oncol. 31, 1748\u20131757 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1339_CR20","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","volume":"173","author":"YM Wu","year":"2018","unstructured":"Wu, Y. M. et al. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173, 1770\u20131782.e14 (2018).","journal-title":"Cell"},{"key":"1339_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758\u2013769.e9 (2018).","journal-title":"Cell"},{"key":"1339_CR22","doi-asserted-by":"crossref","unstructured":"Messina C. et al. BRCA mutations in prostate cancer: prognostic and predictive implications. J. Oncol. 4986365 (2020).","DOI":"10.1155\/2020\/4986365"},{"key":"1339_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/sj.bjc.6604132","volume":"98","author":"A Mitra","year":"2008","unstructured":"Mitra, A. et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br. J. Cancer 98, 502\u2013507 (2008).","journal-title":"Br. J. Cancer"},{"key":"1339_CR24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.eururo.2018.01.010","volume":"73","author":"J Mateo","year":"2018","unstructured":"Mateo, J. et al. Clinical outcome of prostate cancer patients with germline dna repair mutations: retrospective analysis from an international study. Eur. Urol. 73, 687\u2013693 (2018).","journal-title":"Eur. Urol."},{"key":"1339_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eururo.2017.02.023","volume":"72","author":"M Annala","year":"2017","unstructured":"Annala, M. et al. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Eur. Urol. 72, 34\u201342 (2017).","journal-title":"Eur. Urol."},{"key":"1339_CR26","doi-asserted-by":"publisher","first-page":"40222","DOI":"10.18632\/oncotarget.16712","volume":"8","author":"M Cui","year":"2017","unstructured":"Cui, M. et al. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer. Oncotarget 8, 40222\u201340232 (2017).","journal-title":"Oncotarget"},{"key":"1339_CR27","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/pros.21394","volume":"71","author":"L Fachal","year":"2011","unstructured":"Fachal, L. et al. BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data. Prostate 71, 1768\u20131779 (2011).","journal-title":"Prostate"},{"key":"1339_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/pros.23795","volume":"79","author":"M Oh","year":"2019","unstructured":"Oh, M. et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate 79, 880\u2013895 (2019).","journal-title":"Prostate"},{"key":"1339_CR29","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain, M. et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 383, 2345\u20132357 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1339_CR30","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","volume":"29","author":"SM Noordermeer","year":"2019","unstructured":"Noordermeer, S. M. et al. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells. Trends Cell Biol. 29, 820\u2013834 (2019).","journal-title":"Trends Cell Biol."},{"key":"1339_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s13691-025-00761-2","volume":"14","author":"S Miyachi","year":"2025","unstructured":"Miyachi, S. et al. Two Japanese patients with metastatic castration-resistant prostate cancer with somatic biallelic BRCA2 loss and RB1 splice site variant or loss who responded to Poly-ADP-ribose polymerase inhibitor: A case report. Int Cancer Conf. J. 14, 254\u2013258 (2025).","journal-title":"Int Cancer Conf. J."},{"key":"1339_CR32","doi-asserted-by":"crossref","unstructured":"Yoshii, Y. et al. Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy. Life. 11, 796 (2021).","DOI":"10.3390\/life11080796"},{"key":"1339_CR33","doi-asserted-by":"publisher","first-page":"115380","DOI":"10.1016\/j.ejca.2025.115380","volume":"220","author":"R Kitadai","year":"2025","unstructured":"Kitadai, R. et al. Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository. Eur. J. Cancer 220, 115380 (2025).","journal-title":"Eur. J. Cancer"},{"key":"1339_CR34","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","volume":"32","author":"S Halabi","year":"2014","unstructured":"Halabi, S. et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 32, 671\u2013677 (2014).","journal-title":"J. Clin. Oncol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01339-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01339-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01339-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:19:50Z","timestamp":1775650790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01339-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01339-8","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}